Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Aerie Pharmaceuticals, Inc. (AERI)

15.25   0 (0%) 11-18 16:00
Open: 15.24 Pre. Close: 15.25
High: 15.25 Low: 15.24
Volume: 1,215,184 Market Cap: 0(M)

Technical analysis

as of: 2022-12-09 4:20:13 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 17.81     One year: 20.8
Support: Support1: 15.2    Support2: 15.17
Resistance: Resistance1: 15.25    Resistance2: 17.81
Pivot: 15.23
Moving Average: MA(5): 15.24     MA(20): 15.22
MA(100): 12.91     MA(250): 9.7
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 93.3     %D(3): 89.6
RSI: RSI(14): 68.3
52-week: High: 15.36  Low: 4.8
Average Vol(K): 3-Month: 995 (K)  10-Days: 637 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ AERI ] has closed below upper band by 9.1%. Bollinger Bands are 97.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 49 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 15.29 - 15.36 15.36 - 15.42
Low: 15.03 - 15.13 15.13 - 15.22
Close: 15.1 - 15.26 15.26 - 15.39

Company Description

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Headline News

Tue, 22 Nov 2022
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc ... - Business Wire

Tue, 22 Nov 2022
Alcon Completes Acquisition of Aerie Pharmaceuticals - citybiz

Thu, 03 Nov 2022
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results - Business Wire

Mon, 22 Aug 2022
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its ... - Business Wire

Thu, 04 Aug 2022
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial ... - Business Wire

Mon, 01 Aug 2022
Aerie Pharmaceuticals Announces First Participant Dosed in the ... - Business Wire

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 49 (M)
Shares Float 44 (M)
% Held by Insiders 1.7 (%)
% Held by Institutions 103 (%)
Shares Short 1,520 (K)
Shares Short P.Month 1,600 (K)

Stock Financials

EPS -1.48
EPS Est Next Qtl -0.7
EPS Est This Year -2.59
EPS Est Next Year -2.18
Book Value (p.s.) -3.32
Profit Margin (%) -17.1
Operating Margin (%) -12.5
Return on Assets (ttm) -4.6
Return on Equity (ttm) 0
Qtrly Rev. Growth 23.2
Gross Profit (p.s.) 3.38
Sales Per Share 4.32
EBITDA (p.s.) -0.14
Qtrly Earnings Growth 0
Operating Cash Flow 7 (M)
Levered Free Cash Flow 2 (M)

Stock Valuations

PE Ratio -10.38
PEG Ratio 0
Price to Book value -4.6
Price to Sales 3.52
Price to Cash Flow 105.11

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.